Evidence map›Paper›PMID 40056273›Full record

ArticleCell biology and toxicology2025

Targeted nanoparticle delivery system for tumor-associated macrophage reprogramming to enhance TNBC therapy.

Xiaoshen Dong, Xiaoou Wang, Xinyu Zheng, Haiyang Jiang, Lu Liu, Ningye Ma, Shuo Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell biology and toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoshen Dong *Department of Surgical Oncology, Breast Surgery, General Surgery, The First Hospital of China Medical University, 155 North Nanjing St, Shenyang, 110001, China.
Xiaoou Wang *Department of Geriatric Cardiovascular, The First Hospital of China Medical University, 155 North Nanjing St, Shenyang, 110001, China.
Xinyu ZhengDepartment of Surgical Oncology, Breast Surgery, General Surgery, The First Hospital of China Medical University, 155 North Nanjing St, Shenyang, 110001, China.
Haiyang JiangDepartment of Surgical Oncology, Breast Surgery, General Surgery, The First Hospital of China Medical University, 155 North Nanjing St, Shenyang, 110001, China.
Lu LiuDepartment of Surgical Oncology, Breast Surgery, General Surgery, The First Hospital of China Medical University, 155 North Nanjing St, Shenyang, 110001, China.
Ningye MaDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, Liaoning Province, China. maningyehead@163.com.
Shuo WangDepartment of Surgical Oncology, Breast Surgery, General Surgery, The First Hospital of China Medical University, 155 North Nanjing St, Shenyang, 110001, China. swang88@cmu.edu.cn.

Funding

Natural Science Foundation of Liaoning Province 2023-MS-175, 2024-MS-023
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) poses as a daunting and intricate manifestation of breast cancer, highlighted by few treatment options and a poor outlook. The crucial element in fostering tumor growth and immune resistance is the polarization of tumor-associated macrophages (TAMs) into the M2 state within the tumor microenvironment (TME). To address this, we developed M2 targeting peptide-chitosan-curcumin nanoparticles (M2pep-Cs-Cur NPs), a targeted delivery system utilizing chitosan (Cs) as a carrier, curcumin (Cur) as a therapeutic agent, and targeting peptides for specificity. These NPs effectively inhibited TNBC cell proliferation (~ 70%) and invasion (~ 70%), while increasing the responsiveness of tumors to anti-PD-L1 treatment (~ 50% survival enhancement) in vitro and in vivo. Bioinformatics analysis suggested that Cur modulates TAM polarization by influencing key genes such as COX-2, offering insights into its underlying mechanisms. This study highlights the potential of M2pep-Cs-Cur NPs to reverse M2 polarization in TAMs, providing a promising targeted therapeutic strategy to overcome immunotherapy resistance and improve TNBC outcomes.

Indexed as

CurcuminDrug Delivery SystemsNanoparticle Drug Delivery SystemNanoparticlesTriple Negative Breast NeoplasmsTumor-Associated MacrophagesAnimalsCell Line, TumorCell ProliferationChitosanFemaleHumansMacrophagesMiceMice, Inbred BALB CMice, NudeChitosanCurcuminNanoparticle Drug Delivery SystemCOX-2CurcuminImmunotherapy resistanceNanoparticlesReprogrammingTriple-negative breast cancerTumor-associated macrophages

Identifiers

PMID40056273
PMCPMC11890257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.